共 50 条
Lung Transplant in Patients with Connective Tissue Diseases
被引:4
|作者:
Panchabhai, Tanmay S.
[1
,2
]
Abdelrazek, Hesham A.
[1
,2
]
Bremner, Ross M.
[2
,3
]
机构:
[1] St Josephs Hosp, John & Doris Norton Thorac Inst, Lung Transplant Program, 500 West Thomas Rd,Suite 500, Phoenix, AZ 85013 USA
[2] Creighton Univ, Sch Med, Phoenix Campus, Omaha, NE USA
[3] St Josephs Hosp, Thorac Dis & Transplantat, John & Doris Norton Thorac Inst, Norton Thorac Inst, 500 West Thomas Rd,Suite 500, Phoenix, AZ 85013 USA
关键词:
Scleroderma;
Connective tissue disease;
Lung transplant;
Lung allocation score;
Esophageal dysmotility;
Gastroesophageal reflux after lung transplant;
EXTRACORPOREAL MEMBRANE-OXYGENATION;
SYSTEMIC-SCLEROSIS;
GASTROESOPHAGEAL-REFLUX;
INTERNATIONAL SOCIETY;
PULMONARY-FIBROSIS;
SCLERODERMA;
SURVIVAL;
OUTCOMES;
SINGLE;
HEART;
D O I:
10.1016/j.ccm.2019.05.009
中图分类号:
R56 [呼吸系及胸部疾病];
学科分类号:
摘要:
Connective tissue diseases (CTDs) are autoimmune diseases that can result in endstage interstitial lung diseases and pulmonary hypertension. Certain organ system dysfunctions have been thought to affect survival after lung transplant in patients diagnosed with CTDs. This article discusses the current data suggesting that clinical outcomes in patients with CTDs are similar to outcomes of patients who undergo lung transplant for idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease. Larger studies focusing on the management of esophageal dysmotility and strategies of desensitization for increased antibody levels may result in approval of more patients with CTDs for lung transplant.
引用
收藏
页码:637 / +
页数:20
相关论文